Cost-effectiveness of combined atezolizumab/nab-paclitaxel for advanced triple-negative breast cancer.

Mia A Salans,Daniel R Cherry,Anthony T Yip,Patrick Travis Courtney,Abhishek Kumar,James D. Murphy

Cost-effectiveness of combined atezolizumab/nab-paclitaxel for advanced triple-negative breast cancer.

2020

Mia A Salans
Daniel R Cherry
Anthony T Yip
Patrick Travis Courtney
Abhishek Kumar
James D. Murphy

e19388Background: The IMpassion 130 trial found prolonged progression-free and overall survival among PD-L1-positive, advanced triple-negative breast cancer (TNBC) patients receiving atezolizumab a...

Keywords:

Nab-paclitaxel
Triple-negative breast cancer
Oncology
Internal medicine
cost effectiveness
Medicine
Atezolizumab
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations